Evidence map›Paper›PMID 26966700›Full record

ArticleMolecular therapy. Methods & clinical development2016

Development of a real-time imaging system for hypoxic cell apoptosis.

Go Kagiya, Ryohei Ogawa, Fuminori Hyodo, Kei Yamashita, Mizuki Nakamura, Ayumi Ishii, Yukihiko Sejimo, Shintaro Tominaga, Masaharu Murata, Yoshikazu Tanaka and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Go KagiyaSchool of Allied Health Sciences, Kitasato University , Sagamihara, Kanagawa, Japan.
Ryohei OgawaDepartment of Radiological Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama , Sugitani, Toyama, Japan.
Fuminori HyodoInnovation Center for Medical Redox Navigation, Kyushu University , Higashi-ku, Fukuoka, Japan.
Kei YamashitaDivision of Radiation Oncology, Chiba Cancer Center , Chiba, Chiba, Japan.
Mizuki NakamuraDepartment of Diagnostic Radiology, Kitasato University Hospital , Sagamihara, Kanagawa, Japan.
Ayumi IshiiDepartment of Diagnostic Radiology, Saitama Prefectural Cancer Center , Kitaadachi-gun, Saitama, Japan.
Yukihiko SejimoGraduate School of Medicine, Gunma University , Maebashi, Gunma, Japan.
Shintaro TominagaSchool of Allied Health Sciences, Kitasato University , Sagamihara, Kanagawa, Japan.
Masaharu MurataInnovation Center for Medical Redox Navigation, Kyushu University , Higashi-ku, Fukuoka, Japan.
Yoshikazu TanakaBiology Group, The Wakasa Wan Energy Research Center, Nagatani , Tsuruga, Fukui, Japan.
Masanori HatashitaBiology Group, The Wakasa Wan Energy Research Center, Nagatani , Tsuruga, Fukui, Japan.
Foundation Wakasa Wan Energy Research Center · JPKitasato University · JPKyushu University · JPChiba Cancer Center · JPGunma University · JPKitasato University Hospital · JPSaitama Cancer Center · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxic regions within the tumor form due to imbalances between cell proliferation and angiogenesis; specifically, temporary closure or a reduced flow due to abnormal vasculature. They create environments where cancer cells acquire resistance to therapies. Therefore, the development of therapeutic approaches targeting the hypoxic cells is one of the most crucial challenges for cancer regression. Screening potential candidates for effective diagnostic modalities even under a hypoxic environment would be an important first step. In this study, we describe the development of a real-time imaging system to monitor hypoxic cell apoptosis for such screening. The imaging system is composed of a cyclic luciferase (luc) gene under the control of an improved hypoxic-responsive promoter. The cyclic luc gene product works as a caspase-3 (cas-3) monitor as it gains luc activity in response to cas-3 activation. The promoter composed of six hypoxic responsible elements and the CMV IE1 core promoter drives the effective expression of the cyclic luc gene in hypoxic conditions, enhancing hypoxic cell apoptosis visualization. We also confirmed real-time imaging of hypoxic cell apoptosis in the spheroid, which shares properties with the tumor. Thus, this constructed system could be a powerful tool for the development of effective anticancer diagnostic modalities.

Identifiers

PMID26966700
PMCPMC4774642
OpenAlexW2320834614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.